TokyoEnsitrelvir cut COVID infections from 9% to 3% when taken within 72 hours of household exposure, a 2,000-person trial found.
The New England Journal of Medicine study is the first proof an oral drug can prevent COVID after contact.
Japan approved it in March; a US regulatory decision is expected within weeks.
Sources: Nature
THE CONCEPT
Post-exposure prophylaxis means taking a drug AFTER contact with a pathogen but BEFORE symptoms appear, racing to suppress replication during the incubation window. The strategy predates antivirals — rabies immunoglobulin after a dog bite is the classic case.
THE MECHANISM
Ensitrelvir blocks the SARS-CoV-2 main protease (Mpro), an enzyme the virus needs to cut its own proteins into functional pieces. No cleavage, no replication. Pfizer's Paxlovid hits the same target — Mpro is the most druggable site on the coronavirus genome because human cells have no equivalent enzyme.
WHY PAXLOVID WASN'T ENOUGH
Paxlovid contains ritonavir, a booster that blocks liver enzymes (CYP3A4) to keep the antiviral in the bloodstream longer. That same blockade interacts with dozens of common drugs — statins, blood thinners, transplant medications — making it unusable for many of the patients who need it most. Ensitrelvir is a single agent with no ritonavir, avoiding the interaction trap.
THE NUMBERS
A drop from 9% to 3% infection rate is a roughly 67% relative risk reduction. In trial language, the number-needed-to-treat is about 17 — treat 17 exposed contacts to prevent one infection. For comparison, oseltamivir (Tamiflu) post-exposure prophylaxis for influenza shows similar magnitudes.
THE 72-HOUR WINDOW
Antiviral prophylaxis only works if started before viral load explodes. SARS-CoV-2 typically doubles every 6-8 hours in the early days; by day 4-5 post-exposure, peak shedding has begun and drug intervention shifts from prevention to damage control. This is why the trial's enrollment cutoff was 72 hours, not a week.
THE REGULATORY DIVERGENCE
Japan's PMDA approved ensitrelvir for treatment in November 2023 under an emergency pathway; the US FDA has been slower, requesting additional data through 2024. Different agencies weigh trial design choices differently — Japan accepted shorter symptom-resolution endpoints that the FDA viewed as insufficient. The prophylaxis indication now restarts that conversation.